Jazz grows cannabinoid manufacturing ambitions with new $100M...

Jazz grows cannabinoid manufacturing ambitions with new $100M plant to specifically support manufacture of Jazz and GW’s two approved cannabis-based medicines. March 2022

Easier if Jazz Pharma just tipped in some $ to be part of EMD P3 trials Since we kick there Asses twice before

EMD-003 had a greater peak concentration and improved bioavailability compared to an equivalent dose of Epidyolex over a 24 hour period
https://hotcopper.com.au/posts/58301096/single

EMD-RX7 was shown to have more than 4 times the bioavailability compared to an equivalent dose of Epidiolex
https://hotcopper.com.au/posts/60242855/single



Jazz will invest more than $100 million into the 60,000-square-foot facility, where it plans to hire 100-plus staffers once the site is operational The plant is expected to open in 2024, and it will specifically support manufacture of Jazz and GW’s two approved cannabis-based medicines.
https://www.fiercepharma.com/pharma/jazz-and-gw-pharma-grow-cannabinoid-manufacturing-ambitions-new-100m-plant